Anti-CD20 antibody therapy can be effectively and safely administered subcutaneously to patients with MS, even when switching from a prior treatment, two clinical trials suggest.
Measuring the thickness of the retina shortly after diagnosis in multiple sclerosis patients could predict their risk of accumulated disability later in the disease course, say Austrian researchers.